2024年8月,由广东省人民医院吴一龙教授与韩国首尔大学医院Tae Min Kim教授合作的一项国际多中心的II期临床试验(INSIGHT 2研究)发表在权威期刊The Lancet Oncology上,题为“Tepotinib Plus Osimertinib in Patients with EGFR-mutated Non-...
1. Zhao Y, He Y, Wang W, et al. Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic r...
[11] Zhang L, Wang L, Wang J, et al . Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study[J]. Mol Cancer. 2023 Aug 5;2...
et al.Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC). ASCO 2022 Abstract 9013....
[1]AKAMATSU H, TOI Y, HAYASHI H, et al. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized ...
1.https://www.jnj.com/media-center/press-releases/european-commission-approves-rybrevant-amivantamab-in-combination-with-chemotherapy-for-the-treatment-of-adult-patients-with-advanced-egfr-mutated-non-small-cell-lung-cancer-after-failure-of-prior-therapy ...
2. Cho BC, Felip E, Hayashi H, et al. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. Future Oncol. 2022;18(6):639-647. doi:10.2217/fon-2021-0923
关键词 伏美替尼;表皮生长因子受体;酪氨酸激酶抑制剂;非小细胞肺癌;突变;有效性;安全性 Research progress of furmonertinib for EGFR-mutated non-small cell lung cancer GU Hangye,LYU Qing,CHEN Yong(Key Specialty of Clinical Pharmacy,the First Affiliated Hospital of Guangdong Pharmaceutical University,...
谢谢!参考资料 1.Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer | NEJM 2.Efficacy and safety of alflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study. | Journal of Clinical Oncology (ascopubs.org)
et al. Eradicating drug tolerant persisters (DTPs) in EGFR-mutated non small cell lung cancer (NSCLC) by targeting TROP2. World Conference on Lung Cancer. abstr. MA07.06 (2024). Naumov, G. N., Akslen, L. A. & Folkman, J. Role of angiogenesis in human tumor dormancy: animal models ...